Starovasnik Melissa A. sold $31K of TWST
Starovasnik Melissa A. sold 500 shares of Twist Bioscience Corp (TWST) at $61.04 on 2026-05-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale of 500 shares at $61.0400 on 2026-05-26, filed on 2026-05-28, under a pre-arranged 10b5-1 plan.
Market read
A small planned insider sale is unlikely to drive a trading decision by itself, but it can be used as a minor sentiment datapoint.
What to watch
The article provides only the sale size and plan type, not whether there were concurrent buys, option exercises, or broader insider pattern changes.
Background
The article is an SEC Form 4 insider transaction disclosure for Twist Bioscience director Melissa A. Starovasnik.
Ticker impact
Twist Bioscience director Melissa A. Starovasnik sold 500 shares at $61.04 under a pre-arranged 10b5-1 plan, totaling about $30.5K.
Likely minimal impact on TWST price; any effect is more about sentiment than new company information.
The filing is an open-market sale by a director, explicitly under a pre-arranged 10b5-1 plan, and the disclosed value is small relative to typical company market caps.
Market effects
No clear sector read-through from a small, planned insider sale.
None indicated.
None indicated.
Counterpoint
Even planned 10b5-1 sales can coincide with private views; traders may still watch for follow-on insider activity or other disclosures.
Key entities
- issuerTwist Bioscience Corp
Subject of the Form 4 insider transaction disclosure.
- insiderMelissa A. Starovasnik
Director who executed the open-market sale under a 10b5-1 plan.
